Cadre Holdings, Inc.

CDRE

NYSE; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001860543

B

second fifth of 370 graded peers in healthcare

rank 110 of 370; percentile 29.5; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk




Scoreboard	
Profitability	C percentile 45.6
Solvency	B percentile 37.5
Growth and financing	C percentile 43.2
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $770.0M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress, fortress balance sheet
Inputs computable	10 of 14
Graded from	filings received through Mar 10, 2026 232 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$30.59 2026-10-27; market equity $1.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 10, 2026

We are a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets. Our equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Through our dedication to superior quality, we establish a direct covenant with end users that our products will perform and keep them safe when they are most needed.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 45.6						
Gross profitability	33.7%	32.3%		41.6	369	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(2.8%)	(6.6%)		72.0	805	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.4 pts	2.8 pts	23.2	242	2025-12-31
Solvency, sleeve percentile 37.5					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	3.70	(0.33)	22.9	751	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	3.50x	2.94x	52.0	832	2025-12-31
Growth and financing, sleeve percentile 43.2					
Revenue growth, three-year compound	10.1%	10.1%	50.7	413	2025-12-31
Free cash flow growth, three-year compound	10.7%	10.9%	51.6	96	2025-12-31
Reinvestment rate	33.9%	37.1%	50.5	104	2025-12-31
Asset growth, three years	25.2%	2.1%	18.0	697	2025-12-31
Net share issuance, one year	5.2%	2.5%	45.5	634	2026-03-06

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
105	Myriad Genetics Inc. (MYGN)	28.2	B	fortress balance sheet
106	DocGo Inc. (DCGO)	28.5	B	late filer, fortress balance sheet
107	Healthcare Services Group Inc. (HCSG)	28.7	B	
108	Cytokinetics Inc. (CYTK)	29.0	B	short runway
109	Staar Surgical Co. (STAA)	29.3	B	
110	Cadre Holdings, Inc. (CDRE)	29.5	B	
111	MSA Safety Inc. (MSA)	29.8	B	
112	Steris plc (STE)	30.1	B	
113	Agios Pharmaceuticals, Inc. (AGIO)	30.4	B	short runway
114	BioNexus Gene Lab Corp. (BGLC)	30.6	B	dilution, late filer
115	Arcutis Biotherapeutics, Inc. (ARQT)	30.9	B	

What the price implies

at the 2026-10-27 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(17.8%)	7.7%	32
Distance from 52-week high	(33.5%)	(28.6%)	44
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	4.3%	(1.0%)	78
Book value to price	0.26	0.28	48
Sales to price	0.47	0.31	64
Composite equity issuance, five years	not computable	20.5%	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	(0.41)	(0.14)	32

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$54.0M
Operating cash flow, four quarters	$88.4M
Months of runway	not finite
Days since last periodic filing	84 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$12.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$259.6M	2025-12-31	2026-03-10	10-K	26-025862
2	assets	us-gaap:Assets	$770.0M	2025-12-31	2026-03-10	10-K	26-025862
3	net income	us-gaap:NetIncomeLoss	$44.1M	2025-12-31	2026-03-10	10-K	26-025862
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$63.7M	2025-12-31	2026-03-10	10-K	26-025862
5	assets	us-gaap:Assets	$652.7M	2024-12-31	2026-03-10	10-K	26-025862
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$610.3M	2025-12-31	2026-03-10	10-K	26-025862
7	gross profit	us-gaap:GrossProfit	$233.5M	2024-12-31	2026-03-10	10-K	26-025862
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$567.6M	2024-12-31	2026-03-10	10-K	26-025862
9	gross profit	us-gaap:GrossProfit	$200.7M	2023-12-31	2026-03-10	10-K	26-025862
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$482.5M	2023-12-31	2026-03-10	10-K	26-025862
11	gross profit	us-gaap:GrossProfit	$175.7M	2022-12-31	2025-03-11	10-K	25-002711
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$457.8M	2022-12-31	2025-03-11	10-K	25-002711
13	gross profit	us-gaap:GrossProfit	$170.7M	2021-12-31	2024-03-12	10-K	24-002995
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$427.3M	2021-12-31	2024-03-12	10-K	24-002995
15	current assets	us-gaap:AssetsCurrent	$365.9M	2025-12-31	2026-03-10	10-K	26-025862
16	current liabilities	us-gaap:LiabilitiesCurrent	$104.5M	2025-12-31	2026-03-10	10-K	26-025862
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$34.8M	2025-12-31	2026-03-10	10-K	26-025862
18	operating income	us-gaap:OperatingIncomeLoss	$67.4M	2025-12-31	2026-03-10	10-K	26-025862
19	book equity	us-gaap:StockholdersEquity	$317.8M	2025-12-31	2026-03-10	10-K	26-025862
20	liabilities	us-gaap:Liabilities	$452.2M	2025-12-31	2026-03-10	10-K	26-025862
21	operating income	us-gaap:OperatingIncomeLoss	$56.5M	2023-12-31	2026-03-10	10-K	26-025862
22	interest expense	us-gaap:InterestExpense	$4.5M	2023-12-31	2024-03-12	10-K	24-002995
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.9M	2025-12-31	2026-03-10	10-K	26-025862
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$31.8M	2024-12-31	2026-03-10	10-K	26-025862
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.7M	2024-12-31	2026-03-10	10-K	26-025862
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$73.2M	2023-12-31	2026-03-10	10-K	26-025862
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.7M	2023-12-31	2026-03-10	10-K	26-025862
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$46.4M	2022-12-31	2025-03-11	10-K	25-002711
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.5M	2022-12-31	2025-03-11	10-K	25-002711
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$18.6M	2025-12-31	2026-03-10	10-K	26-025862

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$62.3M	2025-12-31	2026-03-10	10-K	26-025862
32	income tax	us-gaap:IncomeTaxExpenseBenefit	$18.2M	2025-12-31	2026-03-10	10-K	26-025862
33	current assets	us-gaap:AssetsCurrent	$327.6M	2024-12-31	2026-03-10	10-K	26-025862
34	current liabilities	us-gaap:LiabilitiesCurrent	$94.1M	2024-12-31	2026-03-10	10-K	26-025862
35	assets	us-gaap:Assets	$431.2M	2023-12-31	2025-03-11	10-K	25-002711
36	assets	us-gaap:Assets	$392.0M	2022-12-31	2024-03-12	10-K	24-002995
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	42,726,564	2026-03-06	2026-03-10	10-K	26-025862
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,607,988	2025-03-06	2025-03-11	10-K	25-002711

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.